Debiopharm is a Swiss biopharmaceutical company founded in 1979, with headquarters in Lausanne and Martigny. The company operates as a group specializing in drug development, drug manufacturing, and digital health investment, focusing on oncology and infectious diseases. Debiopharm aims to develop innovative therapies that meet high unmet medical needs and improve patient quality of life.

The company follows a unique business model that involves in-licensing promising drug candidates, advancing them through clinical development, and out-licensing to large pharmaceutical partners for global commercialization. Debiopharm International is dedicated to developing prescription drugs, while Debiopharm Research & Manufacturing ensures the production of proprietary drugs under GMP standards. Additionally, the Debiopharm Innovation Fund invests in digital health and smart data startups.

Debiopharm has a history of developing key drugs, including triptorelin and oxaliplatin, which have become standards of care. The company collaborates with large pharmaceutical companies, academic institutions, and biotech firms to enhance patient access to its innovative therapies.